Project Grant R01HL181042
Award Date 9/5/25
Completion Date 6/30/29
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19140, USA
Similar Awards
- This Project Grant award of $392,660 from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the role of red blood cells (RBCs) in regulating the inflammatory response during sepsis. The key research objectives are to: 1) establish the subcellular localization of Toll-like Receptor 7 (TLR7) in human RBCs and determine their RNA-sequestration capabilities during sepsis, 2) determine how RBC-expressed TLR7 delivers RNA to...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $418,750.00 to The Feinstein Institutes for Medical Research to conduct research on T cell receptor-mediated T cell activation in neonatal and pediatric sepsis. The goal is to gain insight into how T cell memory influences sepsis-associated organ dysfunction, by comparing responses between human neonates with sepsis and...
- This federal Project Grant award of $423,500.00, provided by the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program, aims to address two critical challenges related to burn sepsis: Identifying distinct immune response phenotypes after burn injury and their relation to sepsis development, in order to enable novel approaches to mitigate sepsis risk. Determining the mechanism by which elevated angiopoietin-2 (ANGPT-2) leads...
- This Project Grant award, in the amount of $187,410, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The grant will support Dr. Hilary Faust, an early-career physician-scientist, in developing novel approaches to identify and target sepsis-associated endothelial dysfunction. The funding will enable Dr. Faust to master advanced techniques for modeling human sepsis-associated endothelial injury...
- The National Heart Lung and Blood Institute, under its Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $412,250 project grant to Arizona State University (ASU) to develop a real-time, automated smart catheter analyzer for early identification of sepsis through continuous monitoring of urine biomarkers. This non-invasive approach aims to enable rapid sepsis diagnosis, within 200 minutes, to support quick clinical intervention and preservation of heart and lung...
- This $479,249 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to understand the molecular mechanisms regulating neutrophil proinflammatory and adhesive activities in sepsis. The project aims to investigate the role of neutrophil A20 signaling in contributing to organ damage in sepsis. Specifically, the research will: 1) Determine the molecular...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $759,983.00 to the University of North Carolina at Chapel Hill to conduct research on the role of neutrophils in lung infections and acute lung injury. The study aims to examine changes in neutrophil transcriptomes and function during Streptococcus pneumoniae pneumonia, with the goal of improving understanding of the lung's immune response and potential...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Chicago to investigate the role of the protein MMP3 in cardiac microvascular barrier dysfunction and heart failure during sepsis. The $762,950 award, effective September 15, 2025 through June 30, 2029, will fund studies to understand how the B1R/MMP3 pathway impacts cardiac microvascular integrity and cardiac function in sepsis. The...
- This Project Grant award of $750,561 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund the SMART-SEPSIS study. The study aims to use electronic health record data and artificial intelligence/machine learning to model individual patient response to sepsis treatment and promote early but reasoned application of the hour-1 sepsis treatment bundle for patients with suspected community-onset lung sepsis. The goal is...
- The Research Foundation for the State University of New York received a $108,512 Project Grant from the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) to develop novel immune-modulating itaconate-loaded telodendrimer nanoparticles to target both hyperinflammation and pyroptosis in sepsis. The project aims to address the current gap in therapies that can directly mitigate excessive cytokine production and immune cell pyroptosis,...